BNP/CALL/ROCHE GS/280/0.1/20.12.24 Share Price

Warrant

DE000PN7C7U9

Delayed Deutsche Boerse AG 15:21:17 01/07/2024 BST
0.46 EUR 0.00% Intraday chart for BNP/CALL/ROCHE GS/280/0.1/20.12.24
Current month+84.00%
1 month+91.67%
Date Price Change
01/07/24 0.46 0.00%
28/06/24 0.46 -6.12%
27/06/24 0.49 +2.08%
26/06/24 0.48 -12.73%
25/06/24 0.55 -12.70%

Delayed Quote Deutsche Boerse AG

Last update July 01, 2024 at 03:21 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PN7C7U
ISINDE000PN7C7U9
Date issued 16/08/2023
Strike 280 CHF
Maturity 20/12/2024 (172 Days)
Parity 10 : 1
Emission price 1.42
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.57
Lowest since issue 0.12
Delta0.24x
Omega 13.69
Premium13.5x
Gearing58.03x
Moneyness 0.8946
Difference Strike 29.9 CHF
Difference Strike %+10.68%
Spread 0.01
Spread %2.22%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus